Nexstim Oyj: Nexstim Plc provides encouraging results of the initial pilot study in severe depression at Kuopio University Hospital
Nexstim Plc provides encouraging results of the initial pilot study in severe depression at Kuopio University Hospital
Nexstim Plc (NXTMH:HEX, NXTMS:STO) ( Nexstim or Company ) provides an overview of results of the pilot study on the use of accelerated iTBS protocol in treatment of severe depression with Nexstim NBT System at Kuopio University Hospital.
Nexstim announces that all 10 patients treated with the accelerated iTBS protocol have completed their 5-day treatment and 7 have completed at least 5 weeks of their planned 12-week follow-up. The 10 patients were treated with shortened treatment sessions to ensure patient safety with the accelerated protocol and no study discontinuations or serious adverse events issues have occurred. All ten patients showed improvement of symptoms on the clinician administered Hamilton Depression Rating Scale (HAM
Nasdaq Stockholm AB: MaxFastigheter i Sverige AB receives observation status (79/21)
Today, March 3, 2021, Stenhus Fastigheter i Norden AB (publ), disclosed a
public takeover offer to the holders of shares and warrants in MaxFastigheter i
Sverige AB.
The rules of Nasdaq First North Growth Market state that a listed company may
be given observation status if the company is subject to a public takeover
offer.
With reference to the above, Nasdaq Stockholm AB decides that the shares (MAXF,
ISIN code SE0008406417, order book ID 123717) and warrants (MAXF TO1, ISIN code
SE0013775699, order book ID 193549) in MaxFastigheter i Sverige AB shall be
given observation status.
Nexstim Plc provides encouraging results of the initial pilot study in severe depression at Kuopio University Hospital globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
Sök
The board of directors of OssDsign has resolved on a fully guaranteed rights issue of approximately SEK 240 million in combination with an over-allotment option of approximately SEK 30 million
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONGKONG, JAPAN, NEW ZEELAND, SINGAPORE, SOUTH AMERICA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE SECTION “IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASE.
The board of directors of OssDsign AB (publ) (”OssDsign” or the ”Company”) has resolved on a rights issue of shares with preferential rights for the Company’s existing shareholders of approximately SEK 240 million (the “Rights Issue”). The Rights Issue is fully covered by subscription undertakings and guarantee commitments
Sök
2cureX announces that the clinical trial of IndiTreat®-guided treatment of metastatic colorectal cancer has met the primary endpoint.
2cureX announced today that its prospective interventional clinical trial investigating the benefit of IndiTreat®-guided treatment achieved its primary endpoint by improving Progression Free Survival (PFS) after eight weeks of treatment. Full data has been submitted to the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting.
2cureX
Publicerad: 1 mars 2021, 13:00
“These results show there’s a significant improvement for patients when treated according to the IndiTreat® test” said Ole Thastrup, 2cureX’s Chief Scientific Officer. “This is an important achievement in this historically hard-to-treat disease. We are deeply appreciative of the cancer patients and clinical investigators who participated in this trial”.